Article
Genfit prunes nearly half its workforce after NASH exit — but CEO promises a future in PBC, diagn
Rating:
0.0
Views:
98
Likes:
1
Library:
1
Two months after Genfit's lead drug, elafibranor, failed a closely-watched Phase III showdown, the French biotech threw in the towel on NASH altogether. Another two months later, top execs are laying off 40% of the workforce — 75 positions in total — as they look to rebuild. The restructuring is
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value